Henry Pharmaceuticals responds to the ruling of the Singapore International Commercial Court: will prove to the arbitration tribunal that the termination of the development of the Noh and Nord drugs company was incorrect.

On August 13, Henry Pharmaceutical released a statement on its official website in response to the further ruling made by the Singapore International Commercial Court. The ruling decided to maintain the interim injunction against KBP and its founder Huang Zhenhua to support the arbitration proceedings initiated by KBP and Novo Nordisk respectively. The statement mentioned that KBP had initiated arbitration proceedings prior to Novo Nordisk. The effectiveness of the injunction sought by Novo Nordisk will be determined in the arbitration proceedings after the ruling by SICC. In the aforementioned ruling, SICC reviewed a series of issues at the core of the dispute, including the conduct of clinical trials and the adequacy of due diligence. The conclusions of SICC will be further reviewed by the arbitration tribunal. Huang Zhenhua stated in this statement that KBP believes that Novo Nordisk's termination of the development of Ocedurenone was wrong, as the drug was expected to benefit patients. KBP will prove this to the arbitration tribunal.